
The Genedrive MT-RNR1 ID Kit has potential benefits in identifying babies at risk of hearing loss from aminoglycoside due to the MT-RNR1 m.1555A>G variant, allowing for alternative antibiotics to be used instead. However, managing the risk of early access is important, including ensuring timely antibiotics, avoiding unnecessary use of alternative antibiotics, and confirming positive results. The economic evidence suggests cost-effectiveness, but upfront costs may be high. Data should be generated in centers with babies from different ethnicities to promote equality.
Recent Posts
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
Breakthroughs in Bladder Cancer Treatments at ASCO GU
Merck unveiled promising bladder cancer treatments at the 2026 ASCO Genitourinary (GU) Cancers Symposium, showcasing data from its portfolio including KEYTRUDA® (pembrolizuma...
Robotic Surgery Portugal: A Landmark Achievement at ULS Viseu Dão-Lafões
Robotic Surgery Portugal Achieves Historic First at ULS Viseu Dão-Lafões
Robotic surgery Portugal has reached a new milestone with the successful first procedure at the Local Health Unit (ULS) Viseu Dão-Lafões...
Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa
Pharmaceutical Tender Investigation Targets Ascendis, Pharma Q, and Sonke
The Competition Commission of South Africa has launched a pharmaceutical tender investigation into manufacturers Ascendis, Pharma Q, and...